CREATE Medicines Announces Positive First-in-Human Results for MT-302
Data demonstrates proof -of-mechanism for In Vivo CAR therapy in solid tumors CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/…
CREATE Medicines and Amsterdam University Medical Center Initiate First In Vivo CAR Therapy Trial in Frontline Setting for Solid Tumors
MT-302, a TROP2-targeting mRNA-LNP in vivo CAR therapy, is the first treatment of its kind to move into a…